By John Harrison, PhD, Scientific Consultant, CRF Health
March and April are traditionally two months that for me involve an unusual amount of business travel. This year has been no exception and in the past 6 weeks I have visited Istanbul, Paris, Vienna, Dallas, Washington, Philadelphia, Cape Town and at the time of writing I am in Tokyo with just Sydney and Melbourne to visit before returning home for Easter. The work has been varied and interesting, including advisory boards, user group presentations and a good number of investigator meetings. What is different about this year is that the indications under discussion have included depression, schizophrenia, ADHD, Parkinson’s disease, Alzheimer’s disease and a variety of other diseases, including hypertension, diabetes and fibromyalgia.